Breast cancer in women at high risk: The role of rapid genetic testing for BRCA1 and -2 mutations and the consequences for treatment strategies

Breast

Volumn 22, Issue 5, 2013, Pages 561-568

  Francken, Anne Brecht ^a   Schouten, Philip C ^a   Bleiker, Eveline M A ^a   Linn, Sabine C ^a   Rutgers, Emiel J Th ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

BRCA1 and 2 mutation; Breast cancer; Rapid testing

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PLATINUM COMPLEX; TAMOXIFEN; TAXANE DERIVATIVE; THIOTEPA; TRASTUZUMAB;

BILATERAL CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CANCER RISK; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HIGH RISK PATIENT; HOMOLOGOUS RECOMBINATION; HUMAN; MASTECTOMY; OVARIECTOMY; OVARY CANCER; PARTIAL MASTECTOMY; PRIORITY JOURNAL; REVIEW; SALPINGOOOPHORECTOMY; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE;

BRCA1 AND -2 MUTATION; BREAST CANCER; RAPID TESTING;

ANTINEOPLASTIC AGENTS; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GENETIC TESTING; HUMANS; MASTECTOMY; MUTATION; NEOADJUVANT THERAPY;

EID: 84884129399     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.07.045     Document Type: Review

References (97)

1. Ferlay J., Parkin D.M., Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010 Mar, 46(4):765-781.
2. Metcalfe K., Lubinski J., Lynch H.T., Ghadirian P., Foulkes W.D., Kim-Sing C., et al. Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations. J Natl Cancer Inst 2010 Dec 15, 102(24):1874-1878.
3. Mohamad H.B., Apffelstaedt J.P. Counseling for male BRCA mutation carriers: a review. Breast 2008 Oct, 17(5):441-450.
4. Antoniou A., Pharoah P.D., Narod S., Risch H.A., Eyfjord J.E., Hopper J.L., et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003 May, 72(5):1117-1130.
5. Ardern-Jones A., Kenen R., Eeles R. Too much, too soon? Patients and health professionals' views concerning the impact of genetic testing at the time of breast cancer diagnosis in women under the age of 40. Eur J Cancer Care (Engl) 2005 Jul, 14(3):272-281.
6. Van Riel E., Warlam-Rodenhuis C.C., Verhoef S., Rutgers E.J., Ausems M.G. BRCA testing of breast cancer patients: medical specialists' referral patterns, knowledge and attitudes to genetic testing. Eur J Cancer Care (Engl) 2010 May, 19(3):369-376.
7. Euhus D.M., Smith K.C., Robinson L., Stucky A., Olopade O.I., Cummings S., et al. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst 2002 Jun 5, 94(11):844-851.
8. Antoniou A.C., Pharoah P.P., Smith P., Easton D.F. The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer 2004 Oct 18, 91(8):1580-1590.
9. Moller P., Hagen A.I., Apold J., Maehle L., Clark N., Fiane B., et al. Genetic epidemiology of BRCA mutations-family history detects less than 50% of the mutation carriers. Eur J Cancer 2007 Jul, 43(11):1713-1717.
10. de Sanjose S., Leone M., Berez V., Izquierdo A., Font R., Brunet J.M., et al. Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients: a population-based study. Int J Cancer 2003 Sep 10, 106(4):588-593.
11. Summaries for patients. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: U.S. Preventive Services Task Force recommendations. Ann Intern Med 2005 Sep 6, 143(5):I47.
12. Richtlijn mammacarcinoom 2012, Ref Type: Internet Communication.
13. Young S.R., Pilarski R.T., Donenberg T., Shapiro C., Hammond L.S., Miller J., et al. The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer 2009, 9:86.
14. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 1999 Aug 4, 91(15):1310-1316.
15. Thompson D., Easton D.F. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002 Sep 18, 94(18):1358-1365.
16. Lubinski J., Phelan C.M., Ghadirian P., Lynch H.T., Garber J., Weber B., et al. Cancer variation associated with the position of the mutation in the BRCA2 gene. Fam Cancer 2004, 3(1):1-10.
17. Liede A., Karlan B.Y., Narod S.A. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 2004 Feb 15, 22(4):735-742.
18. van Asperen C.J., Brohet R.M., Meijers-Heijboer E.J., Hoogerbrugge N., Verhoef S., Vasen H.F., et al. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet 2005 Sep, 42(9):711-719.
19. Garcia-Etienne C.A., Barile M., Gentilini O.D., Botteri E., Rotmensz N., Sagona A., et al. Breast-conserving surgery in BRCA1/2 mutation carriers: are we approaching an answer?. Ann Surg Oncol 2009 Dec, 16(12):3380-3387.
20. Haffty B.G., Harrold E., Khan A.J., Pathare P., Smith T.E., Turner B.C., et al. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet 2002 Apr 27, 359(9316):1471-1477.
21. Brekelmans C.T., Seynaeve C., Menke-Pluymers M., Bruggenwirth H.T., Tilanus-Linthorst M.M., Bartels C.C., et al. Survival and prognostic factors in BRCA1-associated breast cancer. Ann Oncol 2006 Mar, 17(3):391-400.
22. Pierce L.J., Levin A.M., Rebbeck T.R., Ben David M.A., Friedman E., Solin L.J., et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 2006 Jun 1, 24(16):2437-2443.
23. Pierce L.J., Strawderman M., Narod S.A., Oliviotto I., Eisen A., Dawson L., et al. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol 2000 Oct 1, 18(19):3360-3369.
24. Verhoog L.C., Brekelmans C.T., Seynaeve C., van den Bosch L.M., Dahmen G., van Geel A.N., et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 1998 Jan 31, 351(9099):316-321.
25. Trainer A.H., Lewis C.R., Tucker K., Meiser B., Friedlander M., Ward R.L. The role of BRCA mutation testing in determining breast cancer therapy. Nat Rev Clin Oncol 2010 Dec, 7(12):708-717.
26. Kirova Y.M., Stoppa-Lyonnet D., Savignoni A., Sigal-Zafrani B., Fabre N., Fourquet A. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur J Cancer 2005 Oct, 41(15):2304-2311.
27. Pierce L.J., Phillips K.A., Griffith K.A., Buys S., Gaffney D.K., Moran M.S., et al. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat 2010 Jun, 121(2):389-398.
28. Metcalfe K., Lynch H.T., Ghadirian P., Tung N., Kim-Sing C., Olopade O.I., et al. Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 2011 May, 127(1):287-296.
29. Metcalfe K., Lynch H.T., Ghadirian P., Tung N., Olivotto I., Warner E., et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004 Jun 15, 22(12):2328-2335.
30. Verhoog L.C., Brekelmans C.T., Seynaeve C., Meijers-Heijboer E.J., Klijn J.G. Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer. Br J Cancer 2000 Aug, 83(3):384-386.
31. Malone K.E., Begg C.B., Haile R.W., Borg A., Concannon P., Tellhed L., et al. Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol 2010 May 10, 28(14):2404-2410.
32. Meijers-Heijboer H., van Geel B., van Putten W.L., Henzen-Logmans S.C., Seynaeve C., Menke-Pluymers M.B., et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001 Jul 19, 345(3):159-164.
33. van Sprundel T.C., Schmidt M.K., Rookus M.A., Brohet R., van Asperen C.J., Rutgers E.J., et al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer 2005 Aug 8, 93(3):287-292.
34. Metcalfe K.A., Lubinski J., Ghadirian P., Lynch H., Kim-Sing C., Friedman E., et al. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J Clin Oncol 2008 Mar 1, 26(7):1093-1097.
35. Bedrosian I., Hu C.Y., Chang G.J. Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst 2010 Mar 17, 102(6):401-409.
36. Domchek S.M., Friebel T.M., Singer C.F., Evans D.G., Lynch H.T., Isaacs C., et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010 Sep 1, 304(9):967-975.
37. Schwartz M.D., Lerman C., Brogan B., Peshkin B.N., Isaacs C., DeMarco T., et al. Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients. Cancer Epidemiol Biomarkers Prev 2005 Apr, 14(4):1003-1007.
38. Weitzel J.N., McCaffrey S.M., Nedelcu R., MacDonald D.J., Blazer K.R., Cullinane C.A. Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. Arch Surg 2003 Dec, 138(12):1323-1328.
39. Tuttle T.M., Habermann E.B., Grund E.H., Morris T.J., Virnig B.A. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol 2007 Nov 20, 25(33):5203-5209.
40. Sorbero M.E., Dick A.W., Beckjord E.B., Ahrendt G. Diagnostic breast magnetic resonance imaging and contralateral prophylactic mastectomy. Ann Surg Oncol 2009 Jun, 16(6):1597-1605.
41. King T.A., Sakr R., Patil S., Gurevich I., Stempel M., Sampson M., et al. Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol 2011 Jun 1, 29(16):2158-2164.
42. Reding K.W., Bernstein J.L., Langholz B.M., Bernstein L., Haile R.W., Begg C.B., et al. Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer. Breast Cancer Res Treat 2010 Sep, 123(2):491-498.
43. Bertelsen L., Bernstein L., Olsen J.H., Mellemkjaer L., Haile R.W., Lynch C.F., et al. Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study. J Natl Cancer Inst 2008 Jan 2, 100(1):32-40.
44. Fisher B., Dignam J., Wolmark N., DeCillis A., Emir B., Wickerham D.L., et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 1997 Nov 19, 89(22):1673-1682.
45. Alkner S., Bendahl P.O., Ferno M., Nordenskjold B., Ryden L. Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial. Eur J Cancer 2009 Sep, 45(14):2496-2502.
46. Gronwald J., Tung N., Foulkes W.D., Offit K., Gershoni R., Daly M., et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer 2006 May 1, 118(9):2281-2284.
47. Balmana J., Diez O., Rubio I.T., Cardoso F. BRCA in breast cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2011 Sep, 22(Suppl 6):vi31-vi34.
48. Brenner D.J., Shuryak I., Russo S., Sachs R.K. Reducing second breast cancers: a potential role for prophylactic mammary irradiation. J Clin Oncol 2007 Nov 1, 25(31):4868-4872.
49. Rijnsburger A.J., Obdeijn I.M., Kaas R., Tilanus-Linthorst M.M., Boetes C., Loo C.E., et al. BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study. J Clin Oncol 2010 Dec 20, 28(36):5265-5273.
50. Brekelmans C.T., Tilanus-Linthorst M.M., Seynaeve C., vd Ouweland A., Menke-Pluymers M.B., Bartels C.C., et al. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2- B. Eur J Cancer 2007 Mar, 43(5):867-876.
51. Linn S.C. 't Veer LJ. Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept. Eur J Cancer 2009 Sep, 45(Suppl 1):11-26.
52. Turner N., Tutt A., Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004 Oct, 4(10):814-819.
53. Roy R., Chun J., Powell S.N. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer 2012 Jan, 12(1):68-78.
54. Aebi S., Davidson T., Gruber G., Cardoso F. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011 Sep, 22(Suppl 6):vi12-vi24.
55. Cardoso F., Harbeck N., Fallowfield L., Kyriakides S., Senkus E. Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012 Oct, 23(Suppl 7):vii11-vii19.
56. Deans A.J., West S.C. DNA interstrand crosslink repair and cancer. Nat Rev Cancer 2011 Jul, 11(7):467-480.
57. Helleday T. Homologous recombination in cancer development, treatment and development of drug resistance. Carcinogenesis 2010 Jun, 31(6):955-960.
58. Venkitaraman A.R. Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment. Annu Rev Pathol 2009, 4:461-487.
59. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 2008 Aug 1, 26(22):3785-3790.
60. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005 Apr 14, 434(7035):917-921.
61. Chappuis P.O., Goffin J., Wong N., Perret C., Ghadirian P., Tonin P.N., et al. A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J Med Genet 2002 Aug, 39(8):608-610.
62. Lee L.J., Alexander B., Schnitt S.J., Comander A., Gallagher B., Garber J.E., et al. Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers. Cancer 2011 Jul 15, 117(14):3093-3100.
63. Hubert A., Mali B., Hamburger T., Rottenberg Y., Uziely B., Peretz T., et al. Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancer. Fam Cancer 2009, 8(3):173-177.
64. Kriege M., Seynaeve C., Meijers-Heijboer H., Collee J.M., Menke-Pluymers M.B., Bartels C.C., et al. Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2009 Aug 10, 27(23):3764-3771.
65. Fourquet A., Stoppa-Lyonnet D., Kirova Y.M., Sigal-Zafrani B., Asselain B. Familial breast cancer: clinical response to induction chemotherapy or radiotherapy related to BRCA1/2 mutations status. Am J Clin Oncol 2009 Apr, 32(2):127-131.
66. Wong Wong K.A., Al-Rafae M., Chappuis P.O., Brunet J.S., Ghadirian P., Foulkes W.D. Long-term outcome after neo-adjuvant chemotherapy for breast cancer in BRCA1/2 carriers. Int J Cancer 2009 Nov 1, 125(9):2236-2238.
67. Arun B., Bayraktar S., Liu D.D., Gutierrez Barrera A.M., Atchley D., Pusztai L., et al. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol 2011 Oct 1, 29(28):3739-3746.
68. Kriege M., Jager A., Hooning M.J., Huijskens E., Blom J., van Deurzen C.H., et al. The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer 2012 Feb 15, 118(4):899-907.
69. Byrski T., Dent R., Blecharz P., Foszczynska-Kloda M., Gronwald J., Huzarski T., et al. Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Res 2012 Jul 20, 14(4):R110.
70. Silver D.P., Richardson A.L., Eklund A.C., Wang Z.C., Szallasi Z., Li Q., et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 2010 Mar 1, 28(7):1145-1153.
71. Byrski T., Huzarski T., Dent R., Gronwald J., Zuziak D., Cybulski C., et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 2009 May, 115(2):359-363.
72. Fong P.C., Boss D.S., Yap T.A., Tutt A., Wu P., Mergui-Roelvink M., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009 Jul 9, 361(2):123-134.
73. Barber L.J., Sandhu S., Chen L., Campbell J., Kozarewa I., Fenwick K., et al. Secondary Mutations in BRCA2 Associated with Clinical Resistance to a PARP inhibitor. J Pathol 2013 Feb, 229(3):422-429.
74. Gelmon K.A., Tischkowitz M., Mackay H., Swenerton K., Robidoux A., Tonkin K., et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011 Sep, 12(9):852-861.
75. Tutt A., Robson M., Garber J.E., Domchek S.M., Audeh M.W., Weitzel J.N., et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010 Jul 24, 376(9737):235-244.
76. Byrski T., Gronwald J., Huzarski T., Grzybowska E., Budryk M., Stawicka M., et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010 Jan 20, 28(3):375-379.
77. Byrski T., Gronwald J., Huzarski T., Grzybowska E., Budryk M., Stawicka M., et al. Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res Treat 2008 Mar, 108(2):289-296.
78. Robson M.E., Chappuis P.O., Satagopan J., Wong N., Boyd J., Goffin J.R., et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 2004, 6(1):R8-R17.
79. Beelen K., Zwart W., Linn S.C. Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?. Nat Rev Clin Oncol 2012 Sep, 9(9):529-541.
80. Vollebergh M.A., Jonkers J., Linn S.C. Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers. Cell Mol Life Sci 2012 Jan, 69(2):223-245.
81. Sargent D.J., Conley B.A., Allegra C., Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 2005 Mar 20, 23(9):2020-2027.
82. Drost R., Bouwman P., Rottenberg S., Boon U., Schut E., Klarenbeek S., et al. BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. Cancer Cell 2011 Dec 13, 20(6):797-809.
83. Dhillon K.K., Swisher E.M., Taniguchi T. Secondary mutations of BRCA1/2 and drug resistance. Cancer Sci 2011 Apr, 102(4):663-669.
84. Vollebergh M.A., Lips E.H., Nederlof P.M., Wessels L.F., Schmidt M.K., van Beers E.H., et al. An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann Oncol 2011 Jul, 22(7):1561-1570.
85. Schwartz M.D., Peshkin B.N., Hughes C., Main D., Isaacs C., Lerman C. Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sample. J Clin Oncol 2002 Jan 15, 20(2):514-520.
86. Stolier A.J., Fuhrman G.M., Mauterer L., Bolton J.S., Superneau D.W. Initial experience with surgical treatment planning in the newly diagnosed breast cancer patient at high risk for BRCA-1 or BRCA-2 mutation. Breast J 2004 Nov, 10(6):475-480.
87. Braithwaite D., Emery J., Walter F., Prevost A.T., Sutton S. Psychological impact of genetic counseling for familial cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2004 Jan 21, 96(2):122-133.
88. Schwartz M.D., Isaacs C., Graves K.D., Poggi E., Peshkin B.N., Gell C., et al. Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance. Cancer 2012 Jan 15, 118(2):510-517.
89. Daly M.B. Tailoring breast cancer treatment to genetic status: the challenges ahead. J Clin Oncol 2004 May 15, 22(10):1776-1777.
90. Wevers M.R., Hahn D.E., Verhoef S., Bolhaar M.D., Ausems M.G., Aaronson N.K., et al. Breast cancer genetic counseling after diagnosis but before treatment: a pilot study on treatment consequences and psychological impact. Patient Educ Couns 2012 Oct, 89(1):89-95.
91. Zilliacus E., Meiser B., Gleeson M., Watts K., Tucker K., Lobb E.A., et al. Are we being overly cautious? A qualitative inquiry into the experiences and perceptions of treatment-focused germline BRCA genetic testing amongst women recently diagnosed with breast cancer. Support Care Cancer 2012 Nov, 20(11):2949-2958.
92. Vadaparampil S.T., Quinn G.P., Miree C.A., Brzosowicz J., Carter B., Laronga C. Recall of and reactions to a surgeon referral letter for BRCA genetic counseling among high-risk breast cancer patients. Ann Surg Oncol 2009 Jul, 16(7):1973-1981.
93. Wevers M.R., Ausems M.G., Verhoef S., Bleiker E.M., Hahn D.E., Hogervorst F.B., et al. Behavioral and psychosocial effects of rapid genetic counseling and testing in newly diagnosed breast cancer patients: design of a multicenter randomized clinical trial. BMC Cancer 2011, 11:6.
94. Watts K.J., Meiser B., Mitchell G., Kirk J., Saunders C., Peate M., et al. How should we discuss genetic testing with women newly diagnosed with breast cancer? Design and implementation of a randomized controlled trial of two models of delivering education about treatment-focused genetic testing to younger women newly diagnosed with breast cancer. BMC Cancer 2012, 12:320.
95. Tercyak K.P., Peshkin B.N., Brogan B.M., DeMarco T., Pennanen M.F., Willey S.C., et al. Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1/2 gene testing. J Clin Oncol 2007 Jan 20, 25(3):285-291.
96. Frost M.H., Slezak J.M., Tran N.V., Williams C.I., Johnson J.L., Woods J.E., et al. Satisfaction after contralateral prophylactic mastectomy: the significance of mastectomy type, reconstructive complications, and body appearance. J Clin Oncol 2005 Nov 1, 23(31):7849-7856.
97. Le-Petross H.T., Whitman G.J., Atchley D.P., Yuan Y., Gutierrez-Barrera A., Hortobagyi G.N., et al. Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer. Cancer 2011 Sep 1, 117(17):3900-3907.